MRNS Live signals | Maximize Profits with Getagraph.com

SELL 157974 min ago

@ $10.08

Issued: 14 Feb 2024 @ 09:30

Return: -85.91%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 3.70 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders...

Stats
Today's Volume	864 132
Average Volume	2.16M
Market Cap	78.00M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.590 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.00700 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Braunstein Scott	Buy	50 000	Common Stock
2024-03-27	Braunstein Scott	Sell	50 000	Stock Option (Right to Buy)
2024-02-20	Shafer Christina	Sell	2 153	Common Stock
2024-02-20	Manning Martha E	Sell	1 894	Common Stock
2024-02-16	Hulihan Joseph	Sell	2 814	Common Stock

INSIDER POWER
88.36
Last 96 transactions
Buy: 2 669 285 \| Sell: 293 774

Volume Correlation

Long: -0.26 (neutral)

Short: 0.45 (neutral)

Signal:(46.22) Neutral

Marinus Pharmaceuticals Correlation

10 Most Positive Correlations
MBIO	0.955
ALLR	0.947
ZD	0.938
APVO	0.936
PERI	0.935
HOFT	0.933
ISSC	0.929
MPAA	0.927
POAI	0.925
INVE	0.921

10 Most Negative Correlations
GRIN	-0.964
ABIO	-0.948
CSTE	-0.945
GALT	-0.941
NKTR	-0.935
GAIA	-0.935
SLAM	-0.929
AMRK	-0.928
PPTA	-0.927
SGRP	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Marinus Pharmaceuticals Correlation - Currency/Commodity

0.18
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.09
( neutral )

Marinus Pharmaceuticals Financials

Annual	2023
Revenue:	$30.99M
Gross Profit:	$28.50M (91.98 %)
EPS:	$-2.63

FY	2023
Revenue:	$30.99M
Gross Profit:	$28.50M (91.98 %)
EPS:	$-2.63

FY	2022
Revenue:	$25.48M
Gross Profit:	$25.14M (98.67 %)
EPS:	$-0.510

FY	2021
Revenue:	$15.35M
Gross Profit:	$13.87M (90.37 %)
EPS:	$-2.69

Financial Reports:

No articles found.

Marinus Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.